… a sound answer to the patient’s question “is it a cancer?”, the most obvious question is “are
we going to treat it as a cancer?”. New insights have changed the view on LCH and help in …

… splicing alterations as well as mutations in RNA-splicing factors as therapeutic vulnerabilities
in cancer, we discuss ongoing and future efforts to target RNA splicing for cancer therapy. …

… Therefore, the development of new therapeutic approaches for … pathogenesis is critical
to the development of molecularly targeted therapies that might have maximal therapeutic …

… This article focuses on molecularly targeted therapies for malignant glioma, in particular,
those aimed at growth factor receptors (including the epidermal growth factor receptor, the …

… of RON-targeted cancer therapy. Here, we review our current knowledge about MSP–RON
signalling in cancer pathogenesis, discuss the efficacy of targeted RON inhibition for clinical …

Pancreatic cancer is a devastating gastrointestinal cancer characterized by late diagnosis,
limited treatment success and dismal prognosis. Exocrine tumours account for 95% of …

… and the extensive array of targeted therapies being developed for cancer patients, there are
new … profiling and preclinical studies of potentially synergistic combinatorial novel therapies. …

… chain reaction (PCR) analysis on cancer cells captured by laser … from a target therapy with
trastuzumab or pertuzumab [42]. … of therapeutic response for several new targeted therapeutic …

… cancer therapy and is responsible for up to 90% of cancer-related deaths. It exists across all
types of cancer … this pathway and miRNAs in target therapies against cancers are discussed. …

… of the molecular basis of T-ALL, with a particular focus on the role of the NOTCH1 oncogene
and the development of anti-NOTCH1 targeted therapies for the treatment of this disease. …